Disease Domain | Count |
---|---|
Endocrinology and Metabolic Disease | 3 |
Neoplasms | 2 |
Infectious Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Proteolysis-targeting chimeras (PROTAC) | 1 |
Antibody drug conjugate (ADC) | 1 |
Small molecule drug | 1 |
Monoclonal antibody | 1 |
Chemical drugs | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism SARS-CoV-2 S protein inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TTR modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date16 Mar 2024 |
Sponsor / Collaborator |
Start Date01 Feb 2024 |
Sponsor / Collaborator |
Start Date15 Jan 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Nic-15 | Pancreatic Cancer More | Preclinical |
UT28K ( SARS-CoV-2 S protein ) | Coronavirus Infections More | Preclinical |
Benziodarone ( TTR ) | Amyloidosis, Familial More | Preclinical |
SOS1 degradant (University of Central Florida) ( SOS1 ) | Transthyretin Amyloid Cardiomyopathy More | Preclinical |
JP2022132197 ( HERs ) | Neoplasms More | Discovery |